No predictive trends were seen for PD‐L1 tumor proportion score or CPS (Figure 5A,B), EGFR expression (Figure 5A, right panel) or mutation status, tumor mutational burden, or microsatellite instability (data not shown); however, there was a significant reduction in EGFR expression across patients following ASP‐1929 photoimmunotherapy (Figure 5A, right panel). This evidence concerns the gene EGFR and neoplasm.